What Is Smoking Cessation And Nicotine Addiction?

By Author: haven smith
Total Articles: 196
Comment this article

Additional studies are being conducted to aid nicotine addiction patients where the use of smoking e-cigarettes with differential nicotine threshold level to detect and recognize the addictive and rewarding effects of smoking.

Other supportive options include the use of behavioral therapies. A variety of approaches to smoking cessation counseling are available which include cognitive behavioral therapy (CBT) which helps patients identify triggers—the people, places, and things that spur behavior—and teaches them relapse-prevention skills (e.g., relaxation techniques) and effective coping strategies to avoid smoking in the face of stressful situations and triggers.

For More Info @ Smoking Cessation And Nicotine Addiction Market

There are three FDA-approved medications for smoking cessation which include various forms of nicotine replacements (gums, patches, lozenges, nasal spray, and inhalers), bupropion, and varenicline. The first line medications for smoking cessation are NRT and sustained release ...
... (SR) Bupropion. Other medications used as second line treatment are clonidine, nortriptyline and varenicline. Clonididine and Nortriptyline are not approved by the FDA but is off-label preferred as it gives significant results.

The available therapeutics treatment options in Smoking Cessation and Nicotine Addiction Landscape aim to reduce complications arising due to sudden withdrawal of smoking apart from Nicotine Addiction.
The dynamics of the Smoking Cessation and Nicotine Addiction market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world. The launch of emerging therapies is expected during the forecast period of 2020–2030.

Axsome Therapeutics is developing AXS-05, which has completed phase II clinical developmental trial for smoking cessation and nicotine addiction. The drug is a novel, oral, investigational drug product that is under development for the treatment of central nervous system (CNS) disorders. AXS-05 utilizes Axsome’s technology of combining bupropion and dextromethorphan (DM). Bupropion serves to increase the bioavailability of DM and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. AXS-05 is an investigational drug product not approved by the FDA.

Read More @ Smoking Cessation And Nicotine Addiction Market

Cytisine (Cytisinicline) is being developed by Achieve Life Sciences, which is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. The drug is believed to help reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. The drug has shown positive results from the Phase IIb ORCA-1 dose-selection trial for smoking cessation providing a clear path forward for their Phase III trail program. Cytisine is also in phase III trial for nicotine addiction and the trial is being conducted by Loma Linda University in collaboration with Pfizer.

Novo Nordisk is conducting a trial on Liraglutide , which is in phase II developmental stage in patients with smoking cessation. It is a glucagon-like peptide-1 (GLP-1) receptor agonist which is approved under the brand name of Victoza for the treatment of type 2 diabetes mellitus and established cardiovascular disease. The company anticipates the trial to be completed by May 2021.